.gif)
Intas Pharmaceuticals on Friday announced launching of Razumab, a biosimilar to Lucentis (ranibizumab). Novartis' eye drug Lucentis has long had a target on its back from biosimilar makers who would love to get some piece of the $4 billion in annual sales it racks up. Razumab will be 25 per cent cheaper than its imported alternate.
Intas Pharmaceuticals has launched a biosimilar to Lucentis (ranibizumab). Razumab is used for sterile use in the eye and is offered as single dose vial, thus reducing the risk of contamination during use. The biosimilar of ranibizumab, the active ingredient in Lucentis, that it will price at a quarter of the cost of Novartis' drug, according to reliable source.
Subscribe to PharmaTutor News Alerts by Email >>
